Objective: To determine in vitro activity of colistin plus sulbactam against extensive-drug-resistant (XDR) Acinetobacter baumannii.
Material And Method: Checkerboard method was used to determine in vitro activity of colistin plus sulbactam against 11 clinical isolates of XDR A. baumannii. The concentrations of colistin and sulbactam used in the study were 0.025 to 128 mg/ 1 and 4 to 256 mg/l, respectively. Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of colistin, sulbactam and colistin plus sulbactam at various concentrations were determined. Fractional inhibitory concentration index (FICI) was calculated. The antibiotic combination is considered synergistic if FICI < 0.5, indifferent if FICI 0.5 to 4.0, and antagonistic if FICI > 4.0.
Results: Ten isolates of XDR A. baumannii were susceptible to colistin (MIC < 2 mg/l) and one isolate was resistant to colistin (MIC 8 mg/l). There were no antagonistic effects of colistin plus sulbactam against all study isolates. For 10 isolates of colistin-susceptible XDR A. baumannii, some MIC values of the combinations were lower than those of single antibiotics. However no synergistic effect of colistin and sulbactam was observed in colistin-susceptible XDR A. baumannii isolates. The synergistic effect of colistin and sulbactam was detected in some concentrations of colistin and sulbactam against colistin-resistant XDR A. baumannii isolate.
Conclusion: The combination of colistin and sulbactam showed an indifferent effect against colistin-susceptible XDR A. baumannii. The combination of colistin and sulbactam showed synergistic effect at some concentrations of colistin and sulbactam against a clinical isolate of colistin-resistant XDR A. baumannii. In vitro time-kill method should be performed to confirm the aforementioned observations.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Comments on "Effect of colistin combined with sulbactam: 9 g versus 12 g per day on mortality in the treatment of carbapenems resistant Acinetobacter baumannii pneumonia: A randomized controlled trial".
Int J Infect Dis
January 2025
Scientific Research WorkS Peer Support Group (SRWS-PSG), Osaka, Japan; Oku medical clinic, Shimmori 7-1-4, Asahi-ku, Osaka 535-0022, Japan; Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine, School of Public Health, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan. Electronic address:
Antibiotic Resistance Trends in Carbapenem-Resistant Gram-Negative Pathogens and Eight-Year Surveillance of XDR Bloodstream Infections in a Western Greece Tertiary Hospital.
Pathogens
December 2024
Department of Internal Medicine, University Hospital of Patras, 265 04 Patras, Greece.
: The increased prevalence of antibiotic resistance among Gram-negative bacteria presents a severe public health challenge, leading to increased mortality rates, prolonged hospital stays, and higher medical costs. In Greece, the issue of multidrug-resistant Gram-negative bacteria is particularly alarming, exacerbated by overuse of antibiotics and inadequate infection control measures. This study aimed to detect the prevalence of extensively drug-resistant (XDR) Gram-negative bacteria in a tertiary hospital in Western Greece over the last eight years from 2016 to 2023.
View Article and Find Full Text PDFEvaluating the activity of cefoperazone-sulbactam against Gram negative pathogens in blood stream infections using automated systems.
Iran J Microbiol
December 2024
Department of Microbiology, Sher-i-Kashmir Institute of Medical Sciences, Jammu and Kashmir, India.
Background And Objectives: The incidence of multidrug-resistant, Gram-negative organisms, isolated as the etiological agents of infections is ascending. The advent of novel antibiotics poses significant challenges, necessitating the optimization and utilization of extant antimicrobial agents. Cefoperazone, a third-generation cephalosporin and β-lactam antimicrobial, when combined with sulbactam, an irreversible β-lactamase inhibitor, mitigates the vulnerability of cefoperazone to β-lactamase-producing organisms.
View Article and Find Full Text PDFGenetic Characterization of Multidrug-Resistant and Synergy Assessment of Antimicrobial Combinations.
Antibiotics (Basel)
November 2024
Department of Infectious Diseases, University Hospital Dr. José Eleuterio González, Autonomous University of Nuevo Leon, Monterrey 64460, Nuevo Leon, Mexico.
Article Synopsis
- The study investigates the effectiveness of various antimicrobial combinations against multidrug-resistant (MDR) and extensive drug-resistant (XDR) strains of a prominent nosocomial pathogen that poses a significant public health threat.
- Researchers assessed the genetic characteristics of 100 isolates, noting high prevalence of drug resistance genes and variations in expression of efflux pumps and porins, indicating complex resistance mechanisms.
- Two promising combinations, levofloxacin-ampicillin/sulbactam and meropenem-colistin, showed synergistic effects in inhibiting bacterial growth, but differing results across testing methods suggest further research is required to optimize treatment strategies.
Treatment of Carbapenem-Resistant in Real Life (T-ACI): A Prospective Single-Center Observational Study.
Antibiotics (Basel)
October 2024
Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples Federico II, 80131 Naples, Italy.
Carbapenem-resistant (CRAB) poses significant challenges in healthcare due to its multidrug resistance and high mortality rates among critically ill patients. We enrolled 45 patients. Cefiderocol was administered to 40% of patients, often (38.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!